

FAX TRANSMISSION**DATE:** March 7, 2006**PTO IDENTIFIER:** Application Number 09/811,359
Patent Number**Inventor:** Tacyoung Yoon**MESSAGE TO:** US Patent and Trademark Office *ATTN T.W.TRUONG***FAX NUMBER:** (571) 273-~~8300~~ 0676**FROM:** EDWARDS ANGELL PALMER & DODGE LLP
John B. Alexander, Ph.D.**PHONE:** (617) 439-4444**Attorney Dkt. #:** 49662(72021)**PAGES (Including Cover Sheet):** 37**CONTENTS:** Amendment in Response to Final Office Action and Transmittal Pages Filed January 25, 2006
(35 pages)
Copy of acknowledgement facsimile from the USPTO (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 439-4444 and send the original transmission to us by return mail at the address below.

As we discussed today, attached is the submission filed in connection with 09/811,359 on January 25, 2006 and the confirmation facsimile received from the U.S. Patent Office.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

EDWARDS ANGELL PALMER & DODGE LLP
P.O. Box 55874, Boston, Massachusetts 02205
Telephone: (617) 439-4444 Facsimile: (617) 439-4170

BEST AVAILABLE COPY

Docket No.: 49662(72021)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Taeyoung Yoon et al.

Application No.: 09/811,359

Confirmation No.: 7721

Filed: March 16, 2001

Art Unit: 1624

For: 5-SUBSTITUTED ARYLPYRIMIDINES

Examiner: T. N. Truong

AMENDMENT AFTER FINAL ACTION (37 C.F.R. SECTION 1.116)

MS AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Office Action dated December 9, 2005, finally rejecting claims 1, 3, 5-12, 24-27, 30 and 35, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 26 of this paper.